image credit: Unsplash

AACR: Iovance details early responses to TIL cell therapy in lung cancer

April 27, 2020

On April 14, shares of Iovance Biotherapeutics jumped 17%, thanks to three magic words in the title of an abstract the company said will be presented at this week’s virtual meeting of the American Association for Cancer Research (AACR): “durable complete responses.”

The study, which will be discussed Tuesday morning, is a phase 1 clinical trial of Iovance’s highly anticipated tumor-infiltrating lymphocyte (TIL) product in non-small cell lung cancer (NSCLC). How durable were those responses? The abstract, released over the weekend, provides some clues.

Read More on FierceBiotech